Journal article
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Abstract
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
METHODS: We conducted a multicenter, randomized, double-blind, …
Authors
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA
Journal
The New England Journal of Medicine, Vol. 379, No. 22, pp. 2097–2107
Publisher
Massachusetts Medical Society
Publication Date
November 29, 2018
DOI
10.1056/nejmoa1801174
ISSN
0028-4793